http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Clinical course of ulcerative colitis patients who develop acute pancreatitis
Kim, Jong Wook,Hwang, Sung Wook,Park, Sang Hyoung,Song, Tae Jun,Kim, Myung-Hwan,Lee, Ho-Su,Ye, Byong Duk,Yang, Dong-Hoon,Kim, Kyung-Jo,Byeon, Jeong-Sik,Myung, Seung-Jae,Yang, Suk-Kyun Baishideng Publishing Group Inc 2017 WORLD JOURNAL OF GASTROENTEROLOGY Vol.23 No.19
<P><B>AIM</B></P><P>To investigate the clinical course of ulcerative colitis (UC) patients who develop acute pancreatitis.</P><P><B>METHODS</B></P><P>We analyzed 3307 UC patients from the inflammatory bowel disease registry at Asan Medical Center from June 1989 to May 2015. The clinical course of UC patients who developed acute pancreatitis was compared with that of non-pancreatitis UC patients.</P><P><B>RESULTS</B></P><P>Among 51 patients who developed acute pancreatitis, 13 (0.40%) had autoimmune, 10 (0.30%) had aminosalicylate-induced, and 13 (1.73%) had thiopurine-induced pancreatitis. All 13 patients with autoimmune pancreatitis (AIP) had type 2 AIP. Two (15.4%) patients had pre-existing AIP, and three (23.1%) patients developed AIP and UC simultaneously. Compared to non-pancreatitis patients, AIP patients had UC diagnosed at a significantly younger age (median, 22.9 years <I>vs</I> 36.4 years; <I>P</I> = 0.001). AIP and aminosalicylate-induced pancreatitis patients had more extensive UC compared to non-pancreatitis patients. All patients with pancreatitis recovered uneventfully, and there were no recurrences. Biologics were used more frequently in aminosalicylate- and thiopurine-induced pancreatitis patients compared to non-pancreatitis patients [adjusted OR (95%CI), 5.16 (1.42-18.67) and 6.90 (1.83-25.98), respectively]. Biologic utilization rate was similar among AIP and non-pancreatitis patients [OR (95%CI), 0.84 (0.11-6.66)]. Colectomy rates for autoimmune, aminosalicylate-induced, and thiopurine-induced pancreatitis, and for non-pancreatitis patients were 15.4% (2/13), 20% (2/10), 15.4% (2/13), and 7.3% (239/3256), respectively; the rates were not significantly different after adjusting for baseline disease extent.</P><P><B>CONCLUSION</B></P><P>Pancreatitis patients show a non-significant increase in colectomy, after adjusting for baseline disease extent.</P>
Kim Ye Seul,Yoon Jung Won,Kim Dasol,Choi Seunghak,Kim Hyoung Kyu,Youm Jae Boum,Han Jin,Heo Soon Chul,Hyun Sung-Ae,Seo Jung-Wook,Kim Deok-Ho,Kim Jae Ho 생화학분자생물학회 2022 Experimental and molecular medicine Vol.54 No.-
Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) have been reported to exhibit immature embryonic or fetal cardiomyocyte-like phenotypes. To enhance the maturation of hESC-CMs, we identified a natural steroidal alkaloid, tomatidine, as a new substance that stimulates the maturation of hESC-CMs. Treatment of human embryonic stem cells with tomatidine during cardiomyocyte differentiation stimulated the expression of several cardiomyocyte-specific markers and increased the density of T-tubules. Furthermore, tomatidine treatment augmented the number and size of mitochondria and enhanced the formation of mitochondrial lamellar cristae. Tomatidine treatment stimulated mitochondrial functions, including mitochondrial membrane potential, oxidative phosphorylation, and ATP production, in hESC-CMs. Tomatidine-treated hESC-CMs were more sensitive to doxorubicin-induced cardiotoxicity than the control cells. In conclusion, the present study suggests that tomatidine promotes the differentiation of stem cells to adult cardiomyocytes by accelerating mitochondrial biogenesis and maturation and that tomatidine-treated mature hESC-CMs can be used for cardiotoxicity screening and cardiac disease modeling.
Han, Ye Jin,Je, Ju Hui,Kim, So Hyoung,Ahn, Sung Min,Kim, Ha Neui,Kim, Yu Ri,Choi, Young Whan,Shin, Hwa Kyoung,Choi, Byung Tae Institute for Advanced Research in Asian Science a 2014 The American journal of Chinese medicine Vol.42 No.4
<P>Dried roots of Gastrodia elata have traditionally been used in Korean medicine for the treatment of neurological disorders such as scotodinia, paralysis, and epilepsy. In our study, we attempted to investigate the neuroprotective effects of methanol extract from G. elata (MEGE) against glutamate-mediated oxidative stress and to explore underlying neuroprotective mechanisms. Analyses for cell viability, lactate dehydrogenase (LDH), flow cytometry, Western blot, and reactive oxygen species (ROS) were performed in HT22 hippocampal cells. Pretreatment with MEGE resulted in a potent neuroprotective effect against oxidative glutamate toxicity and these effects were exerted mainly by the abrogation of glutamate-induced apoptotic death. Treatment with glutamate resulted in a significant expression of both phosphorylated p38 and dephosphorylated phosphatidylinositol-3-kinase (PI3K). However, pretreatment with MEGE resulted in the inhibition of these expressions. In the inhibitor studies, treatment with PI3K inhibitor LY294002 resulted in the abrogation of the neuroprotective effect of MEGE. In addition, pretreatment with MEGE also resulted in the suppression of the glutamate-induced production of ROS. Treatment with MEGE and anti-oxidant N-acetyl-L-cysteine (NAC) resulted in the enhanced phosphorylation of both PI3K and cAMP responsive element binding protein (CREB), and, in particular, treatment with MEGE resulted in significantly enhanced expression of mature brain-derived neurotrophic factor (BDNF). These results suggest that the extract from G. elata mainly exerted neuroprotective effects through the up-regulation of the PI3K signaling pathway in association with BDNF and may be a useful therapeutic agent for treatment of oxidative neuronal death.</P>
( Hyun Jin Kim ),( Seak Hee Oh ),( Sung Hee Lee ),( Yu-bin Kim ),( Dae Yeon Kim ),( Sang Hyoung Park ),( Byong Duk Ye ),( Suk-kyun Yang ),( Kyung Mo Kim ) 대한간학회 2021 Gut and Liver Vol.15 No.6
Background/Aims: Recently, the treatment of Crohn’s disease (CD) has changed to a treat-to-target strategy, in which disease progression is prevented with early intervention. We analyzed the long-term evolution of nonstricturing, nonpenetrating (B1) disease at diagnosis and factors related to disease evolution in pediatric CD. Methods: We retrospectively analyzed 402 patients between 2000 and 2013 who were younger than 18 years and had B1 disease at CD diagnosis. The median follow-up was 6.1 years (range, 1 to 13 years). The cumulative probabilities of developing stricturing (B2) or penetrating (B3) disease and associations between risk factors and disease behavior evolution were evaluated. Results: Among the 402 patients, 75 (18.7%) had B2 or B3 disease by the final follow-up. The cumulative probabilities of disease behavior evolution were 18.3%, 34.3%, and 50.9% at 5, 10, and 13 years, respectively. Patients whose disease progressed had an increased risk of intestinal resection (hazard ratio [HR], 3.61; 95% confidence interval [CI], 2.25 to 6.03; p<0.001). First-degree family history of inflammatory bowel disease (HR, 2.38; 95% CI, 1.07 to 5.28; p=0.032), isolated ileal involvement at diagnosis (HR, 7.55; 95% CI, 1.04 to 15.57; p=0.045), and positive anti-Saccharomyces cerevisiae antibody titers (HR, 2.10; 95% CI, 1.03 to 4.25; p=0.040) were associated with disease behavior evolution. Early treatment with biologics significantly reduced disease progression (HR, 0.46; 95% CI, 0.79 to 3.39; p=0.042). Conclusions: This study suggests that early aggressive therapy should be considered in B1 behavior pediatric CD patients with risk factors of disease evolution to improve long-term outcomes. (Gut Liver 2021;15:851-857)